Centro de Estudos de Venenos e Animais Peçonhentos, Universidade Estadual Paulista, UNESP, Botucatu, São Paulo State, Brasil.
J Toxicol Environ Health B Crit Rev. 2009 Oct;12(8):553-71. doi: 10.1080/10937400903442514.
Fibrin sealant, a widely available tissue adhesive, has been used since 1940 in a variety of clinical applications. Commercially available fibrin sealant products are synthesized from bovine thrombin and human fibrinogen, which may transmit infectious diseases, and recipients may also develop antibodies against bovine thrombin. Bearing these disadvantages in mind, a new fibrin sealant was developed in 1989 by a group of researchers from the Center for the Study of Venoms and Venomous Animals, in Sao Paulo State, Brazil. The main purpose was to produce an adhesive fibrin without using human blood, to avoid transmitting infectious diseases. The components of this novel sealant were extracted from large animals and a serine proteinase extracted from Crotalus durissus terrificus snake venom. The applicability of this sealant was tested in animals and humans with beneficial results. The new fibrin sealant can be a useful tool clinically due to its flexibility and diversity of applications. This sealant is a biological and biodegradable product that (1) does not produce adverse reactions, (1) contains no human blood, (3) has a good adhesive capacity, (4) gives no transmission of infectious diseases, and (5) may be used as an adjuvant in conventional suture procedures. The effectiveness of this new fibrin sealant is reviewed and its development and employment are described.
纤维蛋白粘合剂作为一种广泛应用的组织粘合剂，自 1940 年以来已在多种临床应用中使用。市售的纤维蛋白粘合剂产品是由牛凝血酶和人纤维蛋白原合成的，这可能会传播传染病，而接受者也可能会产生针对牛凝血酶的抗体。考虑到这些缺点，1989 年，巴西圣保罗州毒液和毒蛇研究中心的一组研究人员开发了一种新型纤维蛋白粘合剂。主要目的是生产一种不使用人血的粘合纤维蛋白，以避免传播传染病。这种新型密封剂的成分是从大型动物中提取的，还有一种丝氨酸蛋白酶是从 Crotalus durissus terrificus 蛇毒液中提取的。该密封剂已在动物和人体上进行了适用性测试，结果良好。由于其灵活性和多种应用，这种新型纤维蛋白粘合剂在临床上可能是一种有用的工具。这种密封剂是一种生物可降解产品，（1）不会产生不良反应，（1）不含人血，（3）具有良好的粘合能力，（4）不会传播传染病，（5）可作为传统缝合过程中的辅助剂。本文回顾了这种新型纤维蛋白粘合剂的有效性，并对其开发和应用进行了描述。
